In a nutshell This study reviewed the recommendations for the treatment and management of patients with multiple myeloma who are not able to undergo stem cell transplantation. Some background Multiple myeloma most frequently affects older patients. The standard treatment option is high-dose chemotherapy followed by stem cell transplantation (SCT)....
Read More
In a nutshell This study compared the effectiveness of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Ozurdex) to lenalidomide and dexamethasone alone in patients with relapsed multiple myeloma. This study concluded that the addition of carfilzomib improved outcomes. Some background Survival rates for multiple myeloma have...
Read MoreIn a nutshell This study compared first-line treatment options for multiple myeloma with and without maintenance therapy. Researchers reported superior treatment outcomes with high-dose melphalan (Alkeran) plus stem cell transplantation when compared to a combination of orally administered treatments. Additional maintenance therapy with lenalidomide...
Read More
In a nutshell This study examined the effectiveness of lenalidomide (Revlimid) and dexamethasone (Ozurdex) in treating patients with newly diagnosed multiple myeloma not eligible for a stem cell transplant. Authors reported superior treatment outcomes with continuous lenalidomide compared to 18 cycles of lenalidomide or...
Read More
In a nutshell This study examined whether lenalidomide (Revlimid) is effective as a maintenance therapy after first-line treatment for multiple myeloma. Researchers concluded that lenalidomide significantly delayed disease progression. Some background High-dose chemotherapy followed by stem cell transplantation is a standard treatment for newly...
Read More
In a nutshell This study compared two induction therapy regimens before high-dose chemotherapy and stem cell (immature blood cell) transplantation (SCT) in patients with multiple myeloma. The authors concluded that the combination of bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (Ozurdex) was more effective than bortezomib,...
Read More
In a nutshell This study examined the safety and effectiveness of ixazomib (Ninlaro) when added to the treatment of relapsed multiple myeloma. Researchers concluded that ixazomib was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background The addition of biologic drugs to standard treatment regimens for...
Read More
In a nutshell This study explored a new method for determining disease risk levels in multiple myeloma. The authors concluded that combining three factors (the ISS score, chromosomal abnormalities, and lactate dehydrogenase levels) offered a clear distinction between three risk groups and their outcomes. Some background Multiple myeloma is a...
Read More
In a nutshell This study explored a new method for determining disease risk levels in multiple myeloma. The authors concluded that combining three factors (the ISS score, chromosomal abnormalities, and lactate dehydrogenase levels) offered a clear distinction between three risk groups and their outcomes. Some background Multiple myeloma is a...
Read More
In a nutshell This study examined the safety and effectiveness of elotuzumab (Empliciti) for relapsed multiple myeloma. Researchers concluded that elotuzumab combined with lenalidomide (Revlimid) and dexamethasone was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background Standard...
Read More
In a nutshell This study compared different treatment combinations for previously untreated multiple myeloma, including bortezomib (Velcade), dexamethasone (Ozurdex), cyclophosphamide (Cytoxan), and lenalidomide (Revlimid). This study concluded that a combination of all four therapies did not improve response rates beyond combinations of three...
Read More
In a nutshell This study examined whether combined treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) is effective without stem cell transplantation (SCT) in patients with multiple myeloma. The authors concluded that RVD followed by SCT led to longer times before disease progression compared to RVD alone. There was no...
Read More
